Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.53 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TOP1 | P11387 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1888404 | 0.82 | FFAR1 (0.50) | FFAR1P2RX7GAAALDH1A1HPGD | |
| SCHEMBL3751729 | 0.82 | P2RX7 (0.64) | P2RX7KCNA5KCNH2GAAALDH1A1 | |
| SCHEMBL4486492 | 0.78 | FFAR1 (0.49) | FFAR1P2RX7KCNA5KCNH2GAA | |
| SCHEMBL4465439 | 0.78 | HPGD (0.59) | FFAR1P2RX7MEN1KMT2AALDH1A1 | |
| SCHEMBL2597682 | 0.78 | ALDH1A1 (0.53) | FFAR1P2RX7GAAHTTMEN1 | |
| SCHEMBL6233047 | 0.78 | HPGD (0.59) | FFAR1P2RX7MEN1KMT2AALDH1A1 | |
| SCHEMBL2644659 | 0.77 | FFAR1 (0.55) | FFAR1MDM2MEN1KMT2AALDH1A1 | |
| SCHEMBL3932445 | 0.77 | ALDH1A1 (0.56) | KCNA5KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL14259788 | 0.76 | FFAR1 (0.46) | FFAR1P2RX7MEN1KMT2AALDH1A1 | |
| SCHEMBL11360187 | 0.75 | FFAR1 (0.46) | FFAR1P2RX7KCNA5GAAMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935832-B2 | Pyrrole and isoindole carboxamide derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2011-05-03 | — | — | US | disclosed |
| US-20100210705-A1 | Pyrrole and Isoindole Carboxamide Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| EP-2142502-A1 | PYRROLE AND ISOINDOLE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008116814-A1 | PYRROLE AND ISOINDOLE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210705-A1 | Pyrrole and Isoindole Carboxamide Derivatives as P2X7 Modulators | P2RX3, P2RX6, P2RY6 | FFAR1 238/4885P2RX7 4/4885KCNA5 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.